PMID- 23346948
OWN - NLM
STAT- MEDLINE
DCOM- 20141006
LR  - 20181202
IS  - 1743-6109 (Electronic)
IS  - 1743-6095 (Linking)
VI  - 10
IP  - 11
DP  - 2013 Nov
TI  - Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients 
      with end-stage renal disease receiving dialysis or after renal transplantation.
PG  - 2798-814
LID - 10.1111/jsm.12038 [doi]
AB  - INTRODUCTION: The phosphodiesterase type 5 (PDE5) inhibitors are generally well 
      tolerated and effective for treating erectile dysfunction (ED), including in 
      patients with significant comorbidity. Because of this benign safety profile, 
      investigators have used PDE5 inhibitors to treat patients with ED and severe 
      renal disease or those who have received renal transplants. AIM: To assess safety 
      and efficacy of PDE5 inhibitors in patients receiving dialysis or renal 
      transplants. MAIN OUTCOME MEASURES: Erectile function as assessed by the 
      International Index of Erectile Function (IIEF) and Global Assessment Questions; 
      adverse events (AEs). METHODS: We reviewed published studies of PDE5 inhibitors 
      in patients receiving dialysis or renal transplants. RESULTS: In double-blind, 
      placebo-controlled studies in patients receiving dialysis or renal transplants, 
      sildenafil significantly improved erectile function as assessed by the IIEF, and 
      75-85% of patients reported improved erectile function on Global Assessment 
      Questions; efficacy was more variable in less well-controlled studies. In >260 
      patients undergoing dialysis who received sildenafil in clinical studies, there 
      were only six reported discontinuations because of AEs (headache [N=3], headache 
      and nausea [N=1], gastrointestinal [N=1], and symptomatic blood pressure decrease 
      [N=1]). In approximately 400 patients with renal transplants who received 
      sildenafil, only three patients discontinued because of AEs. Vardenafil improved 
      IIEF scores of up to 82% of renal transplant recipients in randomized, controlled 
      studies (N=59, total), with no reported discontinuations because of AEs. Limited 
      data also suggest benefit with tadalafil. CONCLUSIONS: ED is common in patients 
      undergoing renal dialysis or postrenal transplant and substantially affects 
      patient quality of life. Sildenafil and vardenafil appear to be efficacious and 
      well tolerated in patients receiving renal dialysis or transplant.
CI  - (c) 2013 International Society for Sexual Medicine.
FAU - Lasaponara, Fedele
AU  - Lasaponara F
AD  - Molinette General and University Hospital, Torino, Italy.
FAU - Sedigh, Omid
AU  - Sedigh O
FAU - Pasquale, Giovanni
AU  - Pasquale G
FAU - Bosio, Andrea
AU  - Bosio A
FAU - Rolle, Luigi
AU  - Rolle L
FAU - Ceruti, Carlo
AU  - Ceruti C
FAU - Timpano, Massimiliano
AU  - Timpano M
FAU - Negro, Carlo Luigi Augusto
AU  - Negro CL
FAU - Paradiso, Matteo
AU  - Paradiso M
FAU - Abbona, Annamaria
AU  - Abbona A
FAU - Segoloni, Giuseppe Paolo
AU  - Segoloni GP
FAU - Fontana, Dario
AU  - Fontana D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130124
PL  - Netherlands
TA  - J Sex Med
JT  - The journal of sexual medicine
JID - 101230693
RN  - 0 (Phosphodiesterase 5 Inhibitors)
SB  - IM
MH  - Adult
MH  - Double-Blind Method
MH  - Erectile Dysfunction/*drug therapy/metabolism/*physiopathology
MH  - Humans
MH  - Kidney Failure, Chronic/metabolism/*physiopathology/surgery/*therapy
MH  - Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Phosphodiesterase 5 Inhibitors/pharmacokinetics/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Renal Dialysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Dialysis
OT  - Erectile Dysfunction
OT  - Kidney
OT  - Liver
OT  - Phosphodiesterase Type 5 Inhibitor
OT  - Safety
OT  - Sildenafil
OT  - Transplant
EDAT- 2013/01/26 06:00
MHDA- 2014/10/07 06:00
CRDT- 2013/01/26 06:00
PHST- 2013/01/26 06:00 [entrez]
PHST- 2013/01/26 06:00 [pubmed]
PHST- 2014/10/07 06:00 [medline]
AID - S1743-6095(15)30201-0 [pii]
AID - 10.1111/jsm.12038 [doi]
PST - ppublish
SO  - J Sex Med. 2013 Nov;10(11):2798-814. doi: 10.1111/jsm.12038. Epub 2013 Jan 24.